234 related articles for article (PubMed ID: 25193892)
1. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
Sany D; Elsawy AE; Elshahawy Y
Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):967-73. PubMed ID: 25193892
[TBL] [Abstract][Full Text] [Related]
2. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
3. Ferroportin in monocytes of hemodialysis patients and its associations with hepcidin, inflammation, markers of iron status and resistance to erythropoietin.
Eleftheriadis T; Pissas G; Remoundou M; Filippidis G; Antoniadi G; Oustampasidou N; Liakopoulos V; Stefanidis I
Int Urol Nephrol; 2014 Jan; 46(1):161-7. PubMed ID: 23860963
[TBL] [Abstract][Full Text] [Related]
4. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
5. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
6. Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients.
El Said HW; Abou Seif KH; Ahmed YS; Abou Elleil HA; El Said TW; Behairy MA; Mohamed MM; Ahmed FA
Nephrology (Carlton); 2018 Apr; 23(4):323-330. PubMed ID: 28130911
[TBL] [Abstract][Full Text] [Related]
7. Hepcidin serum levels and resistance to recombinant human erythropoietin therapy in hemodialysis patients.
Petrulienė K; Žiginskienė E; Kuzminskis V; Nedzelskienė I; Bumblytė IA
Medicina (Kaunas); 2017; 53(2):90-100. PubMed ID: 28416170
[TBL] [Abstract][Full Text] [Related]
8. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
[TBL] [Abstract][Full Text] [Related]
9. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
11. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
12. Hyporesponsiveness to erythropoietin therapy in hemodialyzed patients: potential role of prohepcidin, hepcidin, and inflammation.
Malyszko J; Malyszko JS; Mysliwiec M
Ren Fail; 2009; 31(7):544-8. PubMed ID: 19839848
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
[TBL] [Abstract][Full Text] [Related]
14. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
15. Effects of additional iron doses on hepcidin-25 level in hemodialysis patients without evident iron deficiency.
Brătescu LO; Bârsan L; Gârneaţă L; Stanciu A; Lipan M; Stancu SH; Mircescu G
Int Urol Nephrol; 2014 May; 46(5):1005-12. PubMed ID: 24800994
[TBL] [Abstract][Full Text] [Related]
16. Impact of Inflammation on Ferritin, Hepcidin and the Management of Iron Deficiency Anemia in Chronic Kidney Disease.
Ueda N; Takasawa K
Nutrients; 2018 Aug; 10(9):. PubMed ID: 30150549
[TBL] [Abstract][Full Text] [Related]
17. Hepcidin/Ferritin Ratios Differ Among Non-Dialyzed Chronic Kidney Disease Patients, and Patients on Hemodialysis and Peritoneal Dialysis.
Niikura T; Maruyama Y; Nakashima S; Matsuo N; Tanno Y; Ohkido I; Yokoyama K; Yamamoto H; Yokoo T
Ther Apher Dial; 2019 Aug; 23(4):341-346. PubMed ID: 30411489
[TBL] [Abstract][Full Text] [Related]
18. Effect of protoconized therapy for renal anemia on adverse events of patients with maintenance hemodialysis.
Kuragano T; Yahiro M; Kida A; Furuta M; Nagasawa Y; Hasuike Y; Nanami M; Nakanishi T
Int J Artif Organs; 2014 Dec; 37(12):865-74. PubMed ID: 25450320
[TBL] [Abstract][Full Text] [Related]
19. Plasma carnitine profile during chronic renal anemia treatment with recombinant human erythropoietin.
Debska-Slizień A; Owczarzak A; Kunicka D; Lysiak-Szydłowska W; Rutkowski B
Int J Artif Organs; 2003 Jan; 26(1):33-8. PubMed ID: 12602467
[TBL] [Abstract][Full Text] [Related]
20. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
Grabe DW
Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
